In the wake of the increase in Current Liabilities in the fourth quarter 2024, Quick Ratio fell to 0.01 a new company low.

Within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Quick Ratio than Nymox Pharmaceutical in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 5299 to 5761.

Explain Quick Ratio?
How much Cash & cash equivalents NYMX�s has?
What are NYMX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NYMX Quick Ratio	(Dec 31 2024) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2023) Q4
Y / Y Current Liabilities Change	68.93 %	95.5 %	95.5 %	95.5 %	69.51 %
Y / Y Cash & cash equivalent Change	12.24 %	12.24 %	12.24 %	12.24 %	-93.15 %
Quick Ratio MRQ	0.01	0.01	0.01	0.01	0.01
NYMX's Total Ranking	# 5761	# 5299	# 5414	# 5414	# 5898
Seq. Current Liabilities Change	55.77 %	0 %	0 %	8.45 %	80.26 %
Seq. Cash & cash equivalent Change	0 %	0 %	0 %	12.24 %	0 %

Quick Ratio fourth quarter 2024 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 17
Healthcare Sector	# 1099
Overall Market	# 5428

Quick Ratio Statistics
High	Average	Low
7.4	1.29	0.01
(Dec 31 2018)		(Dec 31 2024)

Financial Statements
Nymox Pharmaceutical's Current Liabilities	$ 12 Millions	Visit NYMX's Balance sheet
Nymox Pharmaceutical's Cash & cash equivalent	$ 0 Millions	Visit NYMX's Balance sheet
Source of NYMX's Sales		Visit NYMX's Sales by Geography

Cumulative Nymox Pharmaceutical's Quick Ratio

NYMX's Quick Ratio for the trailling 12 Months

NYMX Quick Ratio	(Dec 31 2024) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	85.53 %	88.7 %	85.54 %	81.49 %	76.12 %
Y / Y Cash & cash equivalent TTM Growth	12.24 %	-75.19 %	-86.4 %	-95.21 %	-96.23 %
Quick Ratio TTM	0.01	0.01	0.02	0.02	0.02
Total Ranking TTM	# 4196	# 0	# 4076	#	#
Seq. Current Liabilities TTM Growth	16.21 %	14.23 %	16.59 %	19.88 %	18.19 %
Seq. Cash & cash equivalent TTM Growth	2.8 %	2.88 %	2.97 %	3.06 %	-77.28 %

Quick ratio ranking by company, industry and sector >> Back to NYMX Financial Strength Comparisons >> Go to Compare NYMX Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the jump in Current Liabilities in the Q4 2024 to $11.57 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Nymox Pharmaceutical Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 17 other companies have achieved higher Quick Ratio than Nymox Pharmaceutical. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 0 to 4196.

Explain Quick Ratio?
How much Cash & cash equivalents NYMX�s has?
What are NYMX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 18
Healthcare Sector	# 1021
Within the Market	# 4196

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.57	0.53	0.01
(Dec 31 2019)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Dec 31 2024 MRQ Cash & cash equivalent	Dec 31 2024 MRQ Current Liabilities
Nymox Pharmaceutical Corporation	0.01	$ 0.110 Millions	$ 11.572 Millions

Date modified: 2026-08-31T09:28:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.